Questcor Pharmaceuticals (QCOR) 93.60 $QCOR
Infantile Spasm (West Syndrome) Market Analysis - Global API Manufacturers and Phase III Pipeline Assessment, 2014-2015
M2 - Fri Jan 16, 5:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/c96wjx/infantile_spasm) has announced the addition of the "Infantile Spasm (West Syndrome) Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Infantile Spasm (West Syndrome)- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Questcor Pharmaceuticals, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/c9...tile_spasm
QCOR: 93.60 (+1.52)
Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015
at The Street - Tue Jan 06, 10:52AM CST
TheStreet's Adam Feuerstein lays down his predictions for the biotech industry for 2015.
BLUE: 90.70 (+0.93), BIIB: 391.66 (-0.45), QCOR: 93.60 (+1.52), ISIS: 63.86 (-0.43), GILD: 101.90 (+1.10), PFE: 34.64 (-0.23), VVUS: 2.68 (+0.13), JUNO: 40.52 (+0.18), BMY: 60.04 (+0.56), MNKD: 7.00 (+0.02), ARNA: 4.55 (+0.02), PBYI: 205.26 (+2.75), CELG: 115.88 (+0.16)
BioSim Pharmaceuticals to Meet with Industry During JP Morgan Healthcare Conference
Business Wire - Tue Jan 06, 10:22AM CST
Held annually in San Francisco, the JP Morgan Conference, alongside Biotech Showcase and OneMedForum, is one of the largest investment symposia in the healthcare industry. BioSim Pharmaceuticals will be taking advantage of the conference period to meet with potential investors and partners to give exciting news on the progress of their research and development program.
MNK: 115.01 (+2.51), QCOR: 93.60 (+1.52)
Migraine - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/xq8n9b/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Migraine - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ache Laboratorios Farmaceuticos - Alder Biopharmaceuticals - Allergan - Amgen - Astellas Pharma - Avanir Pharmaceuticals - BioDelivery Sciences - Biofrontera - Bristol-Myers Squibb - D-Pharm - Eli Lilly and Company - Heptares Therapeutics - Impax Laboratories - IntelGenx - Istituto Italiano di Tecnologia - Medestea Research & Production - Merck & Co - Nektar Therapeutics - Northern Light Pharmaceuticals - Paladin Labs - Pfizer - Pozen - Proreo Pharma - Questcor Pharmaceuticals - Revance Therapeutics - TheraJect - Transcept Pharmaceuticals - Trigemina - Vertex Pharmaceuticals Incorporated - iCeutica For more information visit http://www.researchandmarkets.com/research/xq8n9b/migraine
VRTX: 113.66 (+4.03), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), NKTR: 13.54 (-0.14), AGN: 229.49 (+1.87), IPXL: 39.51 (+0.69), ALDR: 26.06 (+0.18), QCOR: 93.60 (+1.52), MRK: 58.81 (-0.07), TSPT: 1.70 (-0.04), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15)
401(K) Reconstructed - 2014 Q3 Review
Eric Landis - Seeking Alpha - Tue Oct 28, 9:39AM CDT
Background This article is an update to my 401k portfolio , which I have been profiling as it has been transitioned from investments in mutual funds into a dividend growth portfolio. With the change in investing styles, my focus has also changed...
KMI: 41.97 (+0.21), QCOR: 93.60 (+1.52), COH: 39.85 (+0.64), MAT: 27.61 (+0.17), POT: 37.04 (+0.04), LO: 67.30 (-0.80), O: 52.01 (+0.32), AFL: 62.13 (+0.33)
Anti-Inflammatory Peptides Competitor Analysis Report 2014
M2 - Wed Oct 22, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9jzrgv/competitor) has announced the addition of the "Competitor Analysis: Anti-Inflammatory Peptides" report to their offering. The present Competitive Intelligence Report about peptides therapeutics provides a competitor evaluation in the field of marketed and new molecules for treatment of inflammatory and autoimmune diseases as of September 2014. Anti-Inflammatory peptides under development and on the market are used for treatment of diseases ranging from psoriasis, multiple sclerosis, transplantation and autoimmune diseases.Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently marketed and active projects in research and development of anti-inflammatory peptides. In addition, the report lists company-specific R&D pipelines of anti-inflammatory peptides. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage Key Topics Covered: 1. 2013 Sales of Major Anti-Inflammatory Peptides 2. Cardiovascular Diseases 3. Dermatological Diseases 4. Gastrointestinal Diseases 5. Neurological Diseases 6. Ophthalmological & Otorhino Diseases 7. Pulmonary & Respiratory Diseases 8. Renal Diseases 9. Rheumatological & Autoimmune Diseases 10. Transplantation 11. Not-Specified Inflammatory & Autoimmune Diseases 12. Corporate Anti-Inflammatory Peptide R&D Pipelines Companies Mentioned - 13Therapeutics - Abbvie - Ampio Pharmaceuticals - Araim Pharmaceuticals - Cognosci - Compugen - Dermadis - Digna Biotech - F4 Pharma - FirstString Research - Immunotech Developments - Kineta - Merck Serono - Momenta Pharmaceuticals - Mylan Pharmaceuticals - NeuroVive Pharmaceutical - Novaliq - Novartis (& Sandoz) - Oryn Pharmaceuticals - Polyphor - Protagonist Therapeutics - Proxima Concepts - Questcor Pharmaceuticals - Rogne Bioscience - Santen - Seagarden - Synthon - Teva Pharmaceutical Industries - To-BBB - XTL Biopharmaceuticals For more information visit http://www.researchandmarkets.com/research/9jzrgv/competitor
QCOR: 93.60 (+1.52), MRK: 58.81 (-0.07), CGEN: 8.19 (+0.08), TEVA: 56.77 (-0.58), AMPE: 5.85 (-0.05), MNTA: 11.70 (-0.06), NVS: 102.20 (-0.17)
Greenberg on the Stock Market: Why Investigations No Longer Matter
at The Street - Mon Oct 20, 10:25AM CDT
I can't remember the last time a company got more than a slap on the wrist.
MNK: 115.01 (+2.51), T: 34.66 (+0.05), QCOR: 93.60 (+1.52), GMCR: 118.53 (+0.56), COCO: 0.02 (-0.01)
Mallinckrodt shares rise on earnings outlook
AP - Tue Oct 14, 9:07AM CDT
NEW YORK (AP) — Shares of Mallinckrodt PLC rose Tuesday after the health care products maker posted an earnings outlook for next year that beat Wall Street expectations.
MNK: 115.01 (+2.51), QCOR: 93.60 (+1.52)
Pharmaceutical Industry Confidence Report Q3 2014
M2 - Tue Oct 14, 6:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vkxc2t/pharmaceutical) has announced the addition of the "Pharmaceutical Business Confidence Report Q3 2014" report to their offering. Pharmaceutical Business Confidence Report Q3 2014 is a new report that globally analyzes industry opinions on the latest economic and customer issues, and their impact on investment decisions and growth prospects within the pharmaceutical industry. This report also examines executive opinion with regards to the current and future state of the economy and its retrospective effect on the industry. It analyzes the likely effect of supplier price changes, sales performance, and staff headcount within the industry over July - September 2014. In addition, it provides an overview of the key priorities, threats, and opportunities for the global pharmaceutical industry over July - September 2014. The report features the opinions of pharmaceutical industry respondents about the economic overview covering the following aspects: - State of the economy - Growth prospects and customer confidence - Supplier prices and levels of expenditure - Organizational outlook and strategy Key Highlights - Overall, 43% of pharmaceutical respondents state that they are operating in a favorable economic environment, while 37% state that their current economic conditions are stable - The majority of global pharmaceutical industry respondents anticipate positive growth for both the company and industry over July - September 2014 - Industry respondents from Asia-Pacific expect the highest growth in staff headcount and sales volume in July - September 2014 - Improving operational efficiency and customer retention are the most popular priorities for pharmaceutical industry executives operating across all regions Key Topics Covered: - Economic overview - Methodology and sample size - State of the economy - Growth prospects and consumer confidence - Supplier prices and levels of expenditure - Organizational outlook and strategy - Appendix Companies Mentioned - Alvogen - DAVA Pharmaceuticals - Dream Pharma Corp. - Endo International - Mallinckrodt - Questcor Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/vk...maceutical
QCOR: 93.60 (+1.52)
Michael H. Mulroy and Stephen L. Cartt Joining BioTime Board of Directors
Business Wire - Mon Oct 06, 7:30AM CDT
BioTime, Inc. (NYSE MKT:BTX) announced today that Michael H. Mulroy and Stephen L. Cartt are joining its Board of Directors. Mr. Mulroy has been appointed to the Board to fill a vacancy and Mr. Cartt has been nominated for election to the Board at the Company's upcoming annual shareholders' meeting, which will be held on November 4.
QCOR: 93.60 (+1.52), BTX: 4.07 (+0.05)
Uveitis Market Analysis 2014-2015 - API Manufacturers and Phase III Pipeline Assessment
M2 - Thu Oct 02, 4:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2x3fcg/uveitis_market) has announced the addition of the "Uveitis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Uveitis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Allergan, Inc. - Alcon, Inc. - Horizon Pharma, Inc. - Merck & Co., Inc. - Bausch & Lomb Incorporated - Alcon Laboratories, Inc. - Pharmacia & Upjohn, Inc. - Pfizer Inc. - Roxane Laboratories, Inc. - Falcon Pharmaceuticals, Ltd. - Organon USA Inc. - Apothecon Inc - Schering-Plough Corporation (Inactive) - Merck Sharp & Dohme Corp. - Sanofi - Questcor Pharmaceuticals, Inc. - Sandoz Inc. - Panray Corporation - Novartis AG - UCB, Inc. - Tiber Laboratories, LLC - Concordia Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/2x...tis_market
AGN: 229.49 (+1.87), QCOR: 93.60 (+1.52), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), HZNP: 16.84 (-0.41), NVS: 102.20 (-0.17)
Acquisitions, Clinical Study Results, Dividends, and Technical Updates - Research Reports on Mallinckrodt, Celgene, Actavis, UnitedHealth and Bristol-Myers
PR Newswire - Thu Aug 21, 7:50AM CDT
Today, Analysts Review released its research reports regarding Mallinckrodt PLC (NYSE: MNK), Celgene Corporation (NASDAQ: CELG), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5877-100free.
MNK: 115.01 (+2.51), ACT: 285.37 (+3.71), QCOR: 93.60 (+1.52), UNH: 109.44 (-0.40), BMY: 60.04 (+0.56), CELG: 115.88 (+0.16), CELGZ: 3.17 (-0.04)
Mallinckrodt announces its inclusion in the S&P 500 Index
M2 - Wed Aug 20, 8:09AM CDT
Pharmaceutical company Mallinckrodt (NYSE:MNK) reported on Tuesday that it has now been added to the S&P 500 Index.
MNK: 115.01 (+2.51), QCOR: 93.60 (+1.52)
The Zacks Analyst Blog Highlights:magicJack VocalTec, RRSat Global Communications Network, Enzymotec, Gulfmark Offshore and Questcor Pharmaceuticals
PR Newswire - Tue Aug 19, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the magicJack VocalTec Ltd. (Nasdaq:CALL-Free Report), RRSat Global Communications Network Ltd. (Nasdaq:RRST-Free Report), Enzymotec Ltd. (Nasdaq:ENZY-Free Report), Gulfmark Offshore Inc. (NYSE:GLF-Free Report) and Questcor Pharmaceuticals Inc. (Nasdaq:QCOR-Free Report).
QCOR: 93.60 (+1.52), ENZY: 5.68 (-0.02), RRST: 7.23 (-0.03)
Mallinckrodt Now a Component of the S&P 500 Index
Business Wire - Tue Aug 19, 8:20AM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, announced today that it has become a component of the S&P 500 Index. The inclusion comes following the completion of Mallinckrodt's acquisition of Questcor Pharmaceuticals last week. In addition to increasing the market capitalization of Mallinckrodt, the combination has significantly strengthened the company's balance sheet, cash generation and leverage position.
MNK: 115.01 (+2.51), QCOR: 93.60 (+1.52)
Gulfmark Offshore (GFL) Now Added to S&P SmallCap 600 Index - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 1:00PM CDT
Gulfmark Offshore Inc. (GLF), the provider of offshore marine support and transportation services, will replace Questcor Pharmaceuticals Inc. (QCOR) in the S&P SmallCap 600 after the close of trading on Monday, Aug 18.
QCOR: 93.60 (+1.52), WFT: 12.17 (+0.55), GLF: 19.25 (+0.51), SXL: 44.72 (+0.08)
Mallinckrodt Set to Join the S&P 500; Rowan to Join S&P MidCap 400; GulfMark Offshore to Join S&P SmallCap 600
PR Newswire - Thu Aug 14, 5:07PM CDT
S&P MidCap 400 constituent Mallinckrodt plc (NYSE:MNK) will replace Rowan Companies plc (NYSE:RDC) in the S&P 500, Rowan will replace Mallinckrodt in the S&P MidCap 400, and GulfMark Offshore Inc. (NYSE:GLF) will replace Questcor Pharmaceuticals Inc. (NASD:QCOR) in the S&P SmallCap 600 after the close of trading on Monday, August 18. Mallinckrodt is acquiring Questcor Pharmaceuticals in a deal expected to be completed tonight.
MNK: 115.01 (+2.51), QCOR: 93.60 (+1.52), GLF: 19.25 (+0.51), MHFI: 102.19 (unch), RDC: 23.95 (-0.08)
Mallinckrodt Completes Acquisition Of Questcor Pharmaceuticals
PR Newswire - Thu Aug 14, 3:30PM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that it has completed its acquisition of Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) in a cash and stock transaction valued at approximately $5.8 billion. The acquisition is expected to be immediately accretive to Mallinckrodt's fiscal 2014 adjusted diluted earnings per share and significantly accretive to its adjusted diluted earnings per share in fiscal 2015.
MNK: 115.01 (+2.51), QCOR: 93.60 (+1.52)
Mallinckrodt And Questcor Shareholders Approve Mallinckrodt's Acquisition Of Questcor
PR Newswire - Thu Aug 14, 12:00PM CDT
Mallinckrodt plc (NYSE: MNK) and Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today jointly announced that all proposals necessary for Mallinckrodt's acquisition of Questcor were approved by Mallinckrodt's and Questcor's shareholders at each company's respective shareholder meeting held today.
MNK: 115.01 (+2.51), QCOR: 93.60 (+1.52)
Pharma Equities Coverage -- Pfizer, BioDelivery Sciences Intl., The Medicines, Questcor Pharma, and Nektar Therapeutics
PR Newswire - Tue Aug 12, 8:00AM CDT
On Monday, August 11, 2014, the NASDAQ Composite ended at 4,401.33, up 0.70%, the Dow Jones Industrial Average advanced 0.10%, to finish the day at 16,569.98, and the S&P 500 closed at 1,936.92, up 0.28%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 700.04, up 0.01%, with the index also advancing 4.74 % in the previous three months. Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), BioDelivery Sciences International Inc. (NASDAQ: BDSI), The Medicines Company (NASDAQ: MDCO), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), and Nektar Therapeutics (NASDAQ: NKTR). Free research on these five companies can be accessed at:
BDSI: 14.92 (+0.93), QCOR: 93.60 (+1.52), MDCO: 29.79 (+0.91), PFE: 34.64 (-0.23), NKTR: 13.54 (-0.14)
Infantile Spasm (West Syndrome) Market Analysis - Global API Manufacturers and Phase III Pipeline Assessment, 2014-2015
M2 - Fri Jan 16, 5:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/c96wjx/infantile_spasm) has announced the addition of the "Infantile Spasm (West Syndrome) Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Infantile Spasm (West Syndrome)- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Questcor Pharmaceuticals, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/c9...tile_spasm
QCOR: 93.60 (+1.52)
Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015
at The Street - Tue Jan 06, 10:52AM CST
TheStreet's Adam Feuerstein lays down his predictions for the biotech industry for 2015.
BLUE: 90.70 (+0.93), BIIB: 391.66 (-0.45), QCOR: 93.60 (+1.52), ISIS: 63.86 (-0.43), GILD: 101.90 (+1.10), PFE: 34.64 (-0.23), VVUS: 2.68 (+0.13), JUNO: 40.52 (+0.18), BMY: 60.04 (+0.56), MNKD: 7.00 (+0.02), ARNA: 4.55 (+0.02), PBYI: 205.26 (+2.75), CELG: 115.88 (+0.16)
BioSim Pharmaceuticals to Meet with Industry During JP Morgan Healthcare Conference
Business Wire - Tue Jan 06, 10:22AM CST
Held annually in San Francisco, the JP Morgan Conference, alongside Biotech Showcase and OneMedForum, is one of the largest investment symposia in the healthcare industry. BioSim Pharmaceuticals will be taking advantage of the conference period to meet with potential investors and partners to give exciting news on the progress of their research and development program.
MNK: 115.01 (+2.51), QCOR: 93.60 (+1.52)
Migraine - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/xq8n9b/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Migraine - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ache Laboratorios Farmaceuticos - Alder Biopharmaceuticals - Allergan - Amgen - Astellas Pharma - Avanir Pharmaceuticals - BioDelivery Sciences - Biofrontera - Bristol-Myers Squibb - D-Pharm - Eli Lilly and Company - Heptares Therapeutics - Impax Laboratories - IntelGenx - Istituto Italiano di Tecnologia - Medestea Research & Production - Merck & Co - Nektar Therapeutics - Northern Light Pharmaceuticals - Paladin Labs - Pfizer - Pozen - Proreo Pharma - Questcor Pharmaceuticals - Revance Therapeutics - TheraJect - Transcept Pharmaceuticals - Trigemina - Vertex Pharmaceuticals Incorporated - iCeutica For more information visit http://www.researchandmarkets.com/research/xq8n9b/migraine
VRTX: 113.66 (+4.03), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), NKTR: 13.54 (-0.14), AGN: 229.49 (+1.87), IPXL: 39.51 (+0.69), ALDR: 26.06 (+0.18), QCOR: 93.60 (+1.52), MRK: 58.81 (-0.07), TSPT: 1.70 (-0.04), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15)
401(K) Reconstructed - 2014 Q3 Review
Eric Landis - Seeking Alpha - Tue Oct 28, 9:39AM CDT
Background This article is an update to my 401k portfolio , which I have been profiling as it has been transitioned from investments in mutual funds into a dividend growth portfolio. With the change in investing styles, my focus has also changed...
KMI: 41.97 (+0.21), QCOR: 93.60 (+1.52), COH: 39.85 (+0.64), MAT: 27.61 (+0.17), POT: 37.04 (+0.04), LO: 67.30 (-0.80), O: 52.01 (+0.32), AFL: 62.13 (+0.33)
Anti-Inflammatory Peptides Competitor Analysis Report 2014
M2 - Wed Oct 22, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9jzrgv/competitor) has announced the addition of the "Competitor Analysis: Anti-Inflammatory Peptides" report to their offering. The present Competitive Intelligence Report about peptides therapeutics provides a competitor evaluation in the field of marketed and new molecules for treatment of inflammatory and autoimmune diseases as of September 2014. Anti-Inflammatory peptides under development and on the market are used for treatment of diseases ranging from psoriasis, multiple sclerosis, transplantation and autoimmune diseases.Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently marketed and active projects in research and development of anti-inflammatory peptides. In addition, the report lists company-specific R&D pipelines of anti-inflammatory peptides. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage Key Topics Covered: 1. 2013 Sales of Major Anti-Inflammatory Peptides 2. Cardiovascular Diseases 3. Dermatological Diseases 4. Gastrointestinal Diseases 5. Neurological Diseases 6. Ophthalmological & Otorhino Diseases 7. Pulmonary & Respiratory Diseases 8. Renal Diseases 9. Rheumatological & Autoimmune Diseases 10. Transplantation 11. Not-Specified Inflammatory & Autoimmune Diseases 12. Corporate Anti-Inflammatory Peptide R&D Pipelines Companies Mentioned - 13Therapeutics - Abbvie - Ampio Pharmaceuticals - Araim Pharmaceuticals - Cognosci - Compugen - Dermadis - Digna Biotech - F4 Pharma - FirstString Research - Immunotech Developments - Kineta - Merck Serono - Momenta Pharmaceuticals - Mylan Pharmaceuticals - NeuroVive Pharmaceutical - Novaliq - Novartis (& Sandoz) - Oryn Pharmaceuticals - Polyphor - Protagonist Therapeutics - Proxima Concepts - Questcor Pharmaceuticals - Rogne Bioscience - Santen - Seagarden - Synthon - Teva Pharmaceutical Industries - To-BBB - XTL Biopharmaceuticals For more information visit http://www.researchandmarkets.com/research/9jzrgv/competitor
QCOR: 93.60 (+1.52), MRK: 58.81 (-0.07), CGEN: 8.19 (+0.08), TEVA: 56.77 (-0.58), AMPE: 5.85 (-0.05), MNTA: 11.70 (-0.06), NVS: 102.20 (-0.17)
Greenberg on the Stock Market: Why Investigations No Longer Matter
at The Street - Mon Oct 20, 10:25AM CDT
I can't remember the last time a company got more than a slap on the wrist.
MNK: 115.01 (+2.51), T: 34.66 (+0.05), QCOR: 93.60 (+1.52), GMCR: 118.53 (+0.56), COCO: 0.02 (-0.01)
Mallinckrodt shares rise on earnings outlook
AP - Tue Oct 14, 9:07AM CDT
NEW YORK (AP) — Shares of Mallinckrodt PLC rose Tuesday after the health care products maker posted an earnings outlook for next year that beat Wall Street expectations.
MNK: 115.01 (+2.51), QCOR: 93.60 (+1.52)
Pharmaceutical Industry Confidence Report Q3 2014
M2 - Tue Oct 14, 6:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vkxc2t/pharmaceutical) has announced the addition of the "Pharmaceutical Business Confidence Report Q3 2014" report to their offering. Pharmaceutical Business Confidence Report Q3 2014 is a new report that globally analyzes industry opinions on the latest economic and customer issues, and their impact on investment decisions and growth prospects within the pharmaceutical industry. This report also examines executive opinion with regards to the current and future state of the economy and its retrospective effect on the industry. It analyzes the likely effect of supplier price changes, sales performance, and staff headcount within the industry over July - September 2014. In addition, it provides an overview of the key priorities, threats, and opportunities for the global pharmaceutical industry over July - September 2014. The report features the opinions of pharmaceutical industry respondents about the economic overview covering the following aspects: - State of the economy - Growth prospects and customer confidence - Supplier prices and levels of expenditure - Organizational outlook and strategy Key Highlights - Overall, 43% of pharmaceutical respondents state that they are operating in a favorable economic environment, while 37% state that their current economic conditions are stable - The majority of global pharmaceutical industry respondents anticipate positive growth for both the company and industry over July - September 2014 - Industry respondents from Asia-Pacific expect the highest growth in staff headcount and sales volume in July - September 2014 - Improving operational efficiency and customer retention are the most popular priorities for pharmaceutical industry executives operating across all regions Key Topics Covered: - Economic overview - Methodology and sample size - State of the economy - Growth prospects and consumer confidence - Supplier prices and levels of expenditure - Organizational outlook and strategy - Appendix Companies Mentioned - Alvogen - DAVA Pharmaceuticals - Dream Pharma Corp. - Endo International - Mallinckrodt - Questcor Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/vk...maceutical
QCOR: 93.60 (+1.52)
Michael H. Mulroy and Stephen L. Cartt Joining BioTime Board of Directors
Business Wire - Mon Oct 06, 7:30AM CDT
BioTime, Inc. (NYSE MKT:BTX) announced today that Michael H. Mulroy and Stephen L. Cartt are joining its Board of Directors. Mr. Mulroy has been appointed to the Board to fill a vacancy and Mr. Cartt has been nominated for election to the Board at the Company's upcoming annual shareholders' meeting, which will be held on November 4.
QCOR: 93.60 (+1.52), BTX: 4.07 (+0.05)
Uveitis Market Analysis 2014-2015 - API Manufacturers and Phase III Pipeline Assessment
M2 - Thu Oct 02, 4:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2x3fcg/uveitis_market) has announced the addition of the "Uveitis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Uveitis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Allergan, Inc. - Alcon, Inc. - Horizon Pharma, Inc. - Merck & Co., Inc. - Bausch & Lomb Incorporated - Alcon Laboratories, Inc. - Pharmacia & Upjohn, Inc. - Pfizer Inc. - Roxane Laboratories, Inc. - Falcon Pharmaceuticals, Ltd. - Organon USA Inc. - Apothecon Inc - Schering-Plough Corporation (Inactive) - Merck Sharp & Dohme Corp. - Sanofi - Questcor Pharmaceuticals, Inc. - Sandoz Inc. - Panray Corporation - Novartis AG - UCB, Inc. - Tiber Laboratories, LLC - Concordia Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/2x...tis_market
AGN: 229.49 (+1.87), QCOR: 93.60 (+1.52), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), HZNP: 16.84 (-0.41), NVS: 102.20 (-0.17)
Acquisitions, Clinical Study Results, Dividends, and Technical Updates - Research Reports on Mallinckrodt, Celgene, Actavis, UnitedHealth and Bristol-Myers
PR Newswire - Thu Aug 21, 7:50AM CDT
Today, Analysts Review released its research reports regarding Mallinckrodt PLC (NYSE: MNK), Celgene Corporation (NASDAQ: CELG), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5877-100free.
MNK: 115.01 (+2.51), ACT: 285.37 (+3.71), QCOR: 93.60 (+1.52), UNH: 109.44 (-0.40), BMY: 60.04 (+0.56), CELG: 115.88 (+0.16), CELGZ: 3.17 (-0.04)
Mallinckrodt announces its inclusion in the S&P 500 Index
M2 - Wed Aug 20, 8:09AM CDT
Pharmaceutical company Mallinckrodt (NYSE:MNK) reported on Tuesday that it has now been added to the S&P 500 Index.
MNK: 115.01 (+2.51), QCOR: 93.60 (+1.52)
The Zacks Analyst Blog Highlights:magicJack VocalTec, RRSat Global Communications Network, Enzymotec, Gulfmark Offshore and Questcor Pharmaceuticals
PR Newswire - Tue Aug 19, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the magicJack VocalTec Ltd. (Nasdaq:CALL-Free Report), RRSat Global Communications Network Ltd. (Nasdaq:RRST-Free Report), Enzymotec Ltd. (Nasdaq:ENZY-Free Report), Gulfmark Offshore Inc. (NYSE:GLF-Free Report) and Questcor Pharmaceuticals Inc. (Nasdaq:QCOR-Free Report).
QCOR: 93.60 (+1.52), ENZY: 5.68 (-0.02), RRST: 7.23 (-0.03)
Mallinckrodt Now a Component of the S&P 500 Index
Business Wire - Tue Aug 19, 8:20AM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, announced today that it has become a component of the S&P 500 Index. The inclusion comes following the completion of Mallinckrodt's acquisition of Questcor Pharmaceuticals last week. In addition to increasing the market capitalization of Mallinckrodt, the combination has significantly strengthened the company's balance sheet, cash generation and leverage position.
MNK: 115.01 (+2.51), QCOR: 93.60 (+1.52)
Gulfmark Offshore (GFL) Now Added to S&P SmallCap 600 Index - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 1:00PM CDT
Gulfmark Offshore Inc. (GLF), the provider of offshore marine support and transportation services, will replace Questcor Pharmaceuticals Inc. (QCOR) in the S&P SmallCap 600 after the close of trading on Monday, Aug 18.
QCOR: 93.60 (+1.52), WFT: 12.17 (+0.55), GLF: 19.25 (+0.51), SXL: 44.72 (+0.08)
Mallinckrodt Set to Join the S&P 500; Rowan to Join S&P MidCap 400; GulfMark Offshore to Join S&P SmallCap 600
PR Newswire - Thu Aug 14, 5:07PM CDT
S&P MidCap 400 constituent Mallinckrodt plc (NYSE:MNK) will replace Rowan Companies plc (NYSE:RDC) in the S&P 500, Rowan will replace Mallinckrodt in the S&P MidCap 400, and GulfMark Offshore Inc. (NYSE:GLF) will replace Questcor Pharmaceuticals Inc. (NASD:QCOR) in the S&P SmallCap 600 after the close of trading on Monday, August 18. Mallinckrodt is acquiring Questcor Pharmaceuticals in a deal expected to be completed tonight.
MNK: 115.01 (+2.51), QCOR: 93.60 (+1.52), GLF: 19.25 (+0.51), MHFI: 102.19 (unch), RDC: 23.95 (-0.08)
Mallinckrodt Completes Acquisition Of Questcor Pharmaceuticals
PR Newswire - Thu Aug 14, 3:30PM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that it has completed its acquisition of Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) in a cash and stock transaction valued at approximately $5.8 billion. The acquisition is expected to be immediately accretive to Mallinckrodt's fiscal 2014 adjusted diluted earnings per share and significantly accretive to its adjusted diluted earnings per share in fiscal 2015.
MNK: 115.01 (+2.51), QCOR: 93.60 (+1.52)
Mallinckrodt And Questcor Shareholders Approve Mallinckrodt's Acquisition Of Questcor
PR Newswire - Thu Aug 14, 12:00PM CDT
Mallinckrodt plc (NYSE: MNK) and Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today jointly announced that all proposals necessary for Mallinckrodt's acquisition of Questcor were approved by Mallinckrodt's and Questcor's shareholders at each company's respective shareholder meeting held today.
MNK: 115.01 (+2.51), QCOR: 93.60 (+1.52)
Pharma Equities Coverage -- Pfizer, BioDelivery Sciences Intl., The Medicines, Questcor Pharma, and Nektar Therapeutics
PR Newswire - Tue Aug 12, 8:00AM CDT
On Monday, August 11, 2014, the NASDAQ Composite ended at 4,401.33, up 0.70%, the Dow Jones Industrial Average advanced 0.10%, to finish the day at 16,569.98, and the S&P 500 closed at 1,936.92, up 0.28%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 700.04, up 0.01%, with the index also advancing 4.74 % in the previous three months. Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), BioDelivery Sciences International Inc. (NASDAQ: BDSI), The Medicines Company (NASDAQ: MDCO), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), and Nektar Therapeutics (NASDAQ: NKTR). Free research on these five companies can be accessed at:
BDSI: 14.92 (+0.93), QCOR: 93.60 (+1.52), MDCO: 29.79 (+0.91), PFE: 34.64 (-0.23), NKTR: 13.54 (-0.14)
